5414x • Proven

Co-founder and CEO announced he will step down from his role and the board by the end of 2026.

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25 Co-founder and CEO announced he will step down

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update up 24% year-on-year.

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. Co-founder and CEO announced he will step down